Pfizer’s tafamidis meets primary endpoint in phase 3 transthyretin cardiomyopathy study

This article was originally published here

Pfizer sad its Tafamidis phase 3 transthyretin cardiomyopathy (ATTR-ACT) study evaluating tafamidis for the treatment of transthyretin cardiomyopathy met its primary endpoint, demonstrating a statistically significant reduction in the combination of all-cause mortality and frequency of cardiovascular-related hospitalizations compared to placebo at 30 months

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply